TrialLancet (London, England)2021

Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.

Ruth E Langley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.